InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,949.17
(
-0.60%
)
US TECH 100
20,296.06
(
-0.95%
)
Dow Jones
43,750.86
(
-0.47%
)
Brent Oil
72.21
(
0.48%
)
Bitcoin
87,345.98
(
-3.60%
)
Post# of 253603
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trend-Setter

Send PM Follow Ignore
Followers 13
Posts 1133
Boards Moderated 0
Alias Born 07/19/2013

Trend-Setter

Re: DewDiligence post# 222566

Friday, 11/30/2018 12:41:46 PM

Friday, November 30, 2018 12:41:46 PM

Post# of 253603
"The treatment appeared to be safe and well tolerated and the study confirmed activation of the TLR9 pathway. AZD1419 is an investigational TLR9 agonist developed by Dynavax in collaboration with AstraZeneca. The proposed mechanism of action of AZD1419 is distinct from that of the other TLR9 agonists being developed by Dynavax for immuno-oncology and vaccine applications. AstraZeneca will now review the full data before deciding on the next steps for the AZD1419 program. The data will be presented at a future medical meeting."

Maybe its not over yet? Up to AZN now.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up